株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

アトピー性皮膚炎 (AD):市場考察、疫学、市場予測

Atopic Dermatitis (AD) - Market Insight, Epidemiology and Market Forecast - 2027

発行 DelveInsight Business Research LLP 商品コード 565327
出版日 ページ情報 英文 100 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=110.53円で換算しております。
Back to Top
アトピー性皮膚炎 (AD):市場考察、疫学、市場予測 Atopic Dermatitis (AD) - Market Insight, Epidemiology and Market Forecast - 2027
出版日: 2018年03月01日 ページ情報: 英文 100 Pages
概要

当レポートでは、世界のアトピー性皮膚炎 (AD) の市場について分析し、疾患の概要や現在の治療手法/アルゴリズム、新たな治療薬の開発・上市の動き、主要製品の概要、世界全体および主要国 (米国・欧州諸国・日本) の市場動向 (今後11年間分)、主な市場促進・抑制要因、現在のアンメットニーズ、潜在的な市場機会などについて調査しております。

第1章 イントロダクション

第2章 アトピー性皮膚炎:市場概略

  • 市場シェア構造 (最新値・予測値)

第3章 疾患の背景事情と概要

  • 病因
  • リスク要因
  • 病態生理
  • アトピー性皮膚炎 (AD)
    • ADに伴う掻痒
    • 診断方法

第4章 疫学と患者人口

  • 疾患の定義
  • 患者人口と予測パラメーター
  • 患者人口の計測方法 (米国・欧州・日本)
  • アトピー性皮膚炎の有病者数:主要7ヶ国 (7MM) の場合
  • アトピー性皮膚炎の有病者数:米国
  • アトピー性皮膚炎の有病者数:ドイツ
  • アトピー性皮膚炎の有病者数:フランス
  • アトピー性皮膚炎の有病者数:イタリア
  • アトピー性皮膚炎の有病者数:スペイン
  • アトピー性皮膚炎の有病者数:英国
  • アトピー性皮膚炎の有病者数:日本
  • アトピー性皮膚炎の有病者数:児童 (重症度別)、主要7ヶ国 (7MM) の場合
  • アトピー性皮膚炎の有病者数:成人 (重症度別)、主要7ヶ国 (7MM) の場合
  • アトピー性皮膚炎の有病者数:痒みの程度別、主要7ヶ国 (7MM) の場合
  • アトピー性皮膚炎の有病者数:痒みの程度別 (中程度の場合)、主要7ヶ国 (7MM) の場合
  • 未治療のアトピー性皮膚炎の有病者数:主要7ヶ国 (7MM) の場合
  • 未治療のアトピー性皮膚炎の有病者数:主要7ヶ国 (7MM) の場合、児童/成人別

第5章 治療手法

第6章 治療アルゴリズム

  • 治療の目標
  • 世界各国の治療ガイドライン (米国、日本、欧州)

第7章 治療の失敗

  • アトピー性皮膚炎向け認証済み治療薬

第8章 新規の治療薬

第9章 ネモリズマブ:Galderma Pharma

  • 製品概略
  • 研究開発 (R&D)
  • 製品開発の動き

第10章 トラロキヌマブ:LEO Pharma

第11章 トラジピタント:Vanda Pharmaceuticals

第12章 ZPL-389:Novartis

第13章 NST-141:日本新薬

第14章 セルロピタント:Menlo Therapeutics

第15章 DS107:DS Biopharma

第16章 アシマドリン:Tioga Pharmaceuticals

第17章 GSK2894512:GlaxoSmithKline

第18章 レブリキズマブ:Roche

第19章 DMT210:Dermata Therapeutics

第20章 RVT-501:Roivant Sciences

第21章 OPA-15406:大塚製薬

第22章 現状のアンメットニーズ

第23章 アトピー性皮膚炎:市場分析

  • 市場の将来展望:主要7ヶ国 (7MM) の場合
  • 主要7ヶ国 (7MM) のアトピー性皮膚炎の市場規模

第24章 アトピー性皮膚炎:米国市場の展望

  • 米国の市場規模

第25章 アトピー性皮膚炎:欧州市場の展望

  • ドイツの市場規模
  • フランスの市場規模
  • イタリアの市場規模
  • スペインの市場規模
  • 英国の市場規模

第26章 アトピー性皮膚炎:日本市場の展望

  • 日本の市場規模

第27章 市場促進要因

第28章 市場抑制要因

第29章 専門家の見解

第30章 現在の治療オプションに対する見解

第31章 新規の治療薬に関する見解

第32章 付録

第33章 分析手法

  • 利用した情報源

第34章 DelveInsightのサービス内容

第35章 免責事項

第36章 DelveInsightについて

目次
Product Code: DIMI0253

DelveInsight's 'Atopic Dermatitis - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Atopic Dermatitis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Atopic Dermatitis from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2016-2027

Atopic Dermatitis- Disease Understanding and Treatment Algorithm:

The DelveInsight Atopic Dermatitis market report gives the thorough understanding of the Atopic Dermatitis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Atopic Dermatitis in the US, Europe, and Japan.

Atopic Dermatitis Epidemiology:

The Atopic Dermatitis (AD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.

The disease epidemiology covered in the report is segmented by prevalent population of Atopic Dermatitis, Severity [Children & Adults], Pruritus burden, Pruritus Severity [Moderate to Severe], Uncontrolled Atopic Dermatitis [Children & Adults] in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

According to DelveInsight, the prevalent population of Atopic Dermatitis was estimated to be 40.78 Million [7MM] in 2016 and, is expected to increase at a CAGR of XX% during the study period i.e., 2016-2027. United States accounts for the highest AD Cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. Adults are largely affected with the atopic dermatitis Among EU5, France has been reported to have the highest prevalent population of atopic dermatitis.

Atopic Dermatitis Drug Chapters:

This segment of the Atopic Dermatitis report encloses the detailed analysis of marketed drugs and late stage (Phase-III & Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The drugs marketed for the treatment of Atopic Dermatitis mainly include Dupixent (dupilumab), Eucrisa (crisaborole), Desonate (desonide), Verdeso (desonide), Elidel (pimecrolimus), Protopic (tacrolimus), Allegra (Fexofenadine hydrochloride) and Neoral solution (cyclosporine).

Detailed chapters for all of these drugs, along with the upcoming therapies i.e., [Nemolizumab (Galderma Pharma), Tralokinumab (LEO Pharma), Tradipitant (Vanda Pharmaceuticals), ZPL-389 (Novartis), NST-141 (Nippon Shinyaku), etc., have been covered in the report.

Atopic Dermatitis Market Outlook:

The Atopic Dermatitis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the global market of Atopic Dermatitis was estimated to be USD 2.2 billion in 2016, and is expected to increase at a CAGR of XX% from 2016-2027.

Atopic Dermatitis Drugs Uptake:

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Atopic Dermatitis Report Insights:

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Atopic Dermatitis Report Key Strengths:

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Atopic Dermatitis Report Assessment:

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits:

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Atopic Dermatitis market
  • Organize sales and marketing efforts by identifying the best opportunities for Atopic Dermatitis market
  • To understand the future market competition in the Atopic Dermatitis market.

Table of Contents

1. Report Introduction

2. Atopic Dermatitis Market Overview at a Glance

  • 2.1. Market Share Distribution of Atopic Dermatitis in 2017
  • 2.2. Market Share Distribution of Atopic Dermatitis in 2027

3. Disease Background and Overview

  • 3.1. Etiology
  • 3.2. Risk Factors
  • 3.3. Pathophysiology
  • 3.4. Atopic Dermatitis
    • 3.4.1. Pruritus Associated with Atopic Dermatitis
    • 3.4.2. Diagnosis

4. Epidemiology and Patient Population

  • 4.1. Disease Definition
  • 4.2. Population and Forecast Parameters
  • 4.3. Population Methods
    • 4.3.1. Total prevalent cases in US
    • 4.3.2. EU5
    • 4.3.3. Japan
  • 4.4. Prevalent Population of Atopic Dermatitis in 7MM
  • 4.5. Prevalent Population of Atopic Dermatitis in United States
  • 4.6. Prevalent Population of Atopic Dermatitis in Germany
  • 4.7. Prevalent Population of Atopic Dermatitis in France
  • 4.8. Prevalent Population of Atopic Dermatitis in Italy
  • 4.9. Prevalent Population of Atopic Dermatitis in Spain
  • 4.10. Prevalent Population of Atopic Dermatitis in United Kingdom
  • 4.11. Prevalent Population of Atopic Dermatitis in Japan
  • 4.12. Prevalent Population of Atopic Dermatitis by Severity in 7MM
  • 4.13. Prevalent Population of Atopic Dermatitis by Severity in Children in 7MM
  • 4.14. Prevalent Population of Atopic Dermatitis by Severity in Adults in 7MM
  • 4.15. Prevalent Cases of Atopic Dermatitis by Pruritus Burden in 7MM
  • 4.16. Prevalent Cases of Atopic Dermatitis by Pruritus Severity in Moderate to Severe Cases
  • 4.17. Prevalent Cases with Uncontrolled Atopic Dermatitis in 7MM
  • 4.18. Prevalent Cases with Uncontrolled Atopic Dermatitis in Children and Adults in 7MM

5. Treatment Practices

6. Treatment Algorithm

  • 6.1. Treatment Goals
  • 6.2. Treatment Guidelines by American Academy of Dermatology
  • 6.3. Japanese Guidelines for Atopic Dermatitis 2017
  • 6.4. Guidelines on the Treatment of Atopic Eczema (Atopic Dermatitis): European Dermatology Forum

7. Treatment Failure

  • 7.1. Approved Drugs for Atopic Dermatitis

8. Emerging Therapies

9. Nemolizumab: Galderma Pharma

  • 9.1. Product Description
  • 9.2. Research and Development
  • 9.3. Product Development Activities

10. Tralokinumab: LEO Pharma

  • 10.1. Product Description
  • 10.2. Research and Development
  • 10.3. Product Development Activities

11. Tradipitant: Vanda Pharmaceuticals

  • 11.1. Product Description
  • 11.2. Research and Development
  • 11.3. Product Development Activities

12. ZPL-389: Novartis

  • 12.1. Product Description
  • 12.2. Research and Development
  • 12.3. Product Development Activities

13. NST-141: Nippon Shinyaku

  • 13.1. Product Description
  • 13.2. Research and Development
  • 13.3. Product Development Activities

14. Serlopitant: Menlo Therapeutics

  • 14.1. Product Description
  • 14.2. Research and Development
  • 14.3. Product Development Activities

15. DS107: DS Biopharma

  • 15.1. Product Description
  • 15.2. Research and Development
  • 15.3. Product Development Activities

16. Asimadoline: Tioga Pharmaceuticals

  • 16.1. Product Description
  • 16.2. Research and Development
  • 16.3. Product Development Activities

17. GSK2894512: GlaxoSmithKline

  • 17.1. Product Description
  • 17.2. Research Development Activities
  • 17.3. Product Development Activities

18. Lebrikizumab: Roche

  • 18.1. Product Description
  • 18.2. Research and Development

19. DMT210: Dermata Therapeutics

  • 19.1. Product Description
  • 19.2. Research and Development
  • 19.3. Product Development Activities

20. RVT-501: Roivant Sciences

  • 20.1. Product Description
  • 20.2. Research and Development
  • 20.3. Product Development Activities

21. OPA-15406: Otsuka Pharmaceutical

  • 21.1. Product Description
  • 21.2. Research and Development
  • 21.3. Product Development Activities

22. Current Unmet Need

23. Atopic Dermatitis: Market Analysis

  • 23.1. Market Outlook-7MM
  • 23.2. Market size of Atopic Dermatitis in 7MM

24. Atopic Dermatitis: United States Market Outlook

  • 24.1. United States Market size

25. Atopic Dermatitis: EU5 Market Outlook

  • 25.1. Germany Market size
  • 25.2. France Market size
  • 25.3. Italy Market size
  • 25.4. Spain Market size
  • 25.5. United Kingdom Market size

26. Atopic Dermatitis: Japan Market Outlook

  • 26.1. Japan Market size

27. Market Drivers

28. Market Barriers

29. Expert Opinions

30. Views on Current treatment options

31. Views on emerging therapies

32. Appendix

33. Report Methodology

  • 33.1. Source Used

34. DelevInsight Capabilities

35. Disclaimer

36. About DelveInsight

List of Tables

  • Table 1: Targets focused by companies
  • Table 2: Concept of Atopic Dermatitis by Wise and Sulzberger
  • Table 3: Hanifin and Rajka Diagnostic Criteria
  • Table 4: United Kingdom Working Party diagnostic criteria
  • Table 5: American Academy of Dermatology Diagnostic Criteria
  • Table 6: Japanese Dermatological Association Diagnostic Criteria
  • Table 7: Total Prevalent Population of Atopic Dermatitis in 7 MM (2016-2027)
  • Table 8: Prevalent Population of Atopic Dermatitis in United States (2016-2027)
  • Table 9: Prevalent Population of Atopic Dermatitis in Germany (2016-2027)
  • Table 10: Prevalent Population of Atopic Dermatitis in France (2016-2027)
  • Table 11: Prevalent Population of Atopic Dermatitis in Italy (2016-2027)
  • Table 12: Prevalent Population of Atopic Dermatitis in Spain (2016-2027)
  • Table 13: Prevalent Population of Atopic Dermatitis in United Kingdom (2016-2027)
  • Table 14: Prevalent Population of Atopic Dermatitis in Japan (2016-2027)
  • Table 15: Prevalent Cases of Atopic Dermatitis by Severity in 7MM
  • Table 16: Prevalent Cases of Atopic Dermatitis by Severity in Children in 7MM
  • Table 17: Prevalent Cases of Atopic Dermatitis by Severity in Adult in 7MM
  • Table 18: Total Prevalent Population of Atopic Dermatitis by Pruritus Burden in 7 MM (2016-2027)
  • Table 19: Prevalent Cases of Atopic Dermatitis by Pruritus Severity in Moderate to Severe Cases in 7MM (2016-2027)
  • Table 20: Total Prevalent Population with Uncontrolled Atopic Dermatitis in 7 MM (2016-2027)
  • Table 21:Total Prevalent Population with Uncontrolled Atopic Dermatitis in Children and Adults in 7 MM (2016-2027)
  • Table 22: Topical corticosteroids used for the treatment of Atopic Dermatitis
  • Table 23: Topical Calcineurin Inhibitors (TCIs)
  • Table 24: Topical Phosphodiesterase Type-4 (PDE4) inhibitors
  • Table 25: Oral Corticosteroids
  • Table 26: Biologic medications
  • Table 27: Non-approved systemic immunomodulating agents
  • Table 28: Reasons for noncompliance with medication
  • Table 29: Emerging therapies
  • Table 30: 7 Major Market Size of Atopic Dermatitis in USD Million (2016-2027)
  • Table 31: Market Size of Atopic Dermatitis in United States, USD Millions (2016-2027)
  • Table 32: Market Size of Atopic Dermatitis in Germany , USD Million (2016-2027)
  • Table 33: Market Size of Atopic Dermatitis in France, USD Million (2016-2027)
  • Table 34: Market Size of Atopic Dermatitis in Italy, USD Million (2016-2027)
  • Table 35: Market Size of Atopic Dermatitis in Spain , USD Million (2016-2027)
  • Table 36: Market Size of Atopic Dermatitis in United Kingdom, USD Million (2016-2027)
  • Table 37:Market Size of Atopic Dermatitis in Japan , USD Million (2016-2027)

List of Figures

  • Figure 1: Risk Factors for Atopic Dermatitis
  • Figure 2: Summary of pathogenic mechanisms in acute and chronic atopic dermatitis (AD)
  • Figure 3: Pathophysiology of Pruritus in Atopic Dermatitis
  • Figure 4: Mediators involved in Pathophysiology of Pruritus in Atopic Dermatitis
  • Figure 5: Total Prevalent Population of Atopic Dermatitis in 7 MM (2016-2027)
  • Figure 6: Total Prevalent Population of Atopic Dermatitis in United States (2016-2027)
  • Figure 7: Total Prevalent Population of Atopic Dermatitis in Germany (2016-2027)
  • Figure 8: Total Prevalent Population of Atopic Dermatitis in France (2016-2027)
  • Figure 9: Total Prevalent Population of Atopic Dermatitis in Italy (2016-2027)
  • Figure 10: Total Prevalent Population of Atopic Dermatitis in Spain (2016-2027)
  • Figure 11: Total Prevalent Population of Atopic Dermatitis in the United Kingdom (2016-2027)
  • Figure 12: Total Prevalent Population of Atopic Dermatitis in Japan (2016-2027)
  • Figure 13: Total Prevalent Population of Atopic Dermatitis by Severity in 7 MM (2016-2027)
  • Figure 14: Total Prevalent Population of Atopic Dermatitis by Severity in Children in 7 MM (2016-2027)
  • Figure 15: Total Prevalent Population of Atopic Dermatitis by Severity in Adult in 7 MM (2016-2027)
  • Figure 16: Total Prevalent Population of Atopic Dermatitis by Pruritus Burden in 7 MM (2016-2027)
  • Figure 17: Prevalent Cases of Atopic Dermatitis by Pruritus Severity in Moderate to Severe Cases in 7MM (2016-2027)
  • Figure 18: Total Prevalent Population with Uncontrolled Atopic Dermatitis in 7 MM (2016-2027)
  • Figure 19:Total Prevalent Population with Uncontrolled Atopic Dermatitis in Children and Adults in 7 MM (2016-2027)
  • Figure 20: General Treatment for Atopic Dermatitis
  • Figure 21: First Line and second line treatment of Atopic Dermatitis
  • Figure 22: Current stepped treatment options for Atopic dermatitis
  • Figure 23: Current Unmet Need for Atopic Dermatitis
  • Figure 24: 7 Major Market Size of Atopic Dermatitis in USD Million (2016-2027)
  • Figure 25: Market Size of Atopic Dermatitis in United States, USD Millions (2016-2027)
  • Figure 26: Market Size of Atopic Dermatitis in Germany , USD Million (2016-2027)
  • Figure 27: Market Size of Atopic Dermatitis in France, USD Million (2016-2027)
  • Figure 28: Market Size of Dermatitis in Italy, USD Million (2016-2027)
  • Figure 29: Market Size of Atopic Dermatitis in Spain, USD Million (2016-2027)
  • Figure 30: Market Size of Atopic Dermatitis in United Kingdom , USD Million (2016-2027)
  • Figure 31:Market Size of Atopic Dermatitis in Japan , USD Million (2016-2027)
Back to Top